Published in J Neurosci on January 20, 2010
mTOR is a key modulator of ageing and age-related disease. Nature (2013) 5.40
TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity. Proc Natl Acad Sci U S A (2013) 3.33
Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat. Nature (2012) 3.08
Mitochondria: the next (neurode)generation. Neuron (2011) 3.06
Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α-synuclein. J Neurosci (2011) 2.53
Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med (2012) 1.99
Rapamycin activates autophagy and improves myelination in explant cultures from neuropathic mice. J Neurosci (2010) 1.92
Tsc1 (hamartin) confers neuroprotection against ischemia by inducing autophagy. Nat Med (2013) 1.89
Rhes, a striatal-enriched small G protein, mediates mTOR signaling and L-DOPA-induced dyskinesia. Nat Neurosci (2011) 1.74
Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurol (2015) 1.66
Stressin' Sestrins take an aging fight. EMBO Mol Med (2010) 1.65
Regulation of presynaptic neurotransmission by macroautophagy. Neuron (2012) 1.52
Parkinson's disease and cancer: two wars, one front. Nat Rev Cancer (2011) 1.45
Drugs that modulate aging: the promising yet difficult path ahead. Transl Res (2013) 1.38
Mitophagy and Parkinson's disease: the PINK1-parkin link. Biochim Biophys Acta (2010) 1.34
Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease. Redox Biol (2013) 1.24
Hot topics in aging research: protein translation and TOR signaling, 2010. Aging Cell (2011) 1.22
Neurotoxin-induced ER stress in mouse dopaminergic neurons involves downregulation of TRPC1 and inhibition of AKT/mTOR signaling. J Clin Invest (2012) 1.21
TOR on the brain. Exp Gerontol (2010) 1.18
Mitochondrial autophagy in cells with mtDNA mutations results from synergistic loss of transmembrane potential and mTORC1 inhibition. Hum Mol Genet (2011) 1.18
Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin. Prog Neurobiol (2012) 1.13
Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism. J Biol Chem (2011) 1.12
Protein degradation pathways in Parkinson's disease: curse or blessing. Acta Neuropathol (2012) 1.07
The role of mTOR signaling in Alzheimer disease. Front Biosci (Schol Ed) (2012) 1.05
Mammalian target of rapamycin (mTOR) pathways in neurological diseases. Biomed J (2013) 1.03
RTP801/REDD1 regulates the timing of cortical neurogenesis and neuron migration. J Neurosci (2011) 0.96
Erythropoietin: new directions for the nervous system. Int J Mol Sci (2012) 0.95
Oxidant stress and signal transduction in the nervous system with the PI 3-K, Akt, and mTOR cascade. Int J Mol Sci (2012) 0.94
mTOR Inhibition: From Aging to Autism and Beyond. Scientifica (Cairo) (2013) 0.94
Endogenous dynorphin protects against neurotoxin-elicited nigrostriatal dopaminergic neuron damage and motor deficits in mice. J Neuroinflammation (2012) 0.94
Activation of the macroautophagic system in scrapie-infected experimental animals and human genetic prion diseases. Autophagy (2012) 0.93
α-Synuclein and neuronal cell death. Mol Neurobiol (2012) 0.92
Parkinson's disease as a result of aging. Aging Cell (2015) 0.92
WISP1 neuroprotection requires FoxO3a post-translational modulation with autoregulatory control of SIRT1. Curr Neurovasc Res (2013) 0.91
Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases. Curr Pharm Des (2011) 0.90
The role of mTOR signaling pathway in spinal cord injury. Cell Cycle (2012) 0.90
A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR. Future Neurol (2012) 0.90
Impairment of Atg5-dependent autophagic flux promotes paraquat- and MPP⁺-induced apoptosis but not rotenone or 6-hydroxydopamine toxicity. Toxicol Sci (2013) 0.90
Rapamycin ameliorates cadmium-induced activation of MAPK pathway and neuronal apoptosis by preventing mitochondrial ROS inactivation of PP2A. Neuropharmacology (2016) 0.89
Dysregulated mTORC1-Dependent Translational Control: From Brain Disorders to Psychoactive Drugs. Front Behav Neurosci (2011) 0.88
GM-CSF induces neuroprotective and anti-inflammatory responses in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxicated mice. J Neuroimmunol (2013) 0.87
Autophagic activity in neuronal cell death. Neurosci Bull (2015) 0.86
Lysosomes and α-synuclein form a dangerous duet leading to neuronal cell death. Front Neuroanat (2014) 0.86
Rapamycin, Autophagy, and Alzheimer's Disease. J Biochem Pharmacol Res (2013) 0.86
Mitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotection. Parkinsons Dis (2010) 0.86
Activation of AMPK and inactivation of Akt result in suppression of mTOR-mediated S6K1 and 4E-BP1 pathways leading to neuronal cell death in in vitro models of Parkinson's disease. Cell Signal (2014) 0.86
α-Synuclein levels modulate Huntington's disease in mice. Hum Mol Genet (2011) 0.86
Treatment of geographic atrophy with subconjunctival sirolimus: results of a phase I/II clinical trial. Invest Ophthalmol Vis Sci (2013) 0.85
Alleviation of neuronal energy deficiency by mTOR inhibition as a treatment for mitochondria-related neurodegeneration. Elife (2016) 0.84
Rapamycin improves motor function, reduces 4-hydroxynonenal adducted protein in brain, and attenuates synaptic injury in a mouse model of synucleinopathy. Pathobiol Aging Age Relat Dis (2015) 0.83
Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease. Neurobiol Dis (2014) 0.83
Intracellular signalling pathways in dopamine cell death and axonal degeneration. Prog Brain Res (2010) 0.83
Parkin loss of function contributes to RTP801 elevation and neurodegeneration in Parkinson's disease. Cell Death Dis (2014) 0.82
Inhibition of mammalian target of rapamycin improves neurobehavioral deficit and modulates immune response after intracerebral hemorrhage in rat. J Neuroinflammation (2014) 0.82
Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria-related disorders. Br J Clin Pharmacol (2016) 0.82
Adaptive changes in autophagy after UPS impairment in Parkinson's disease. Acta Pharmacol Sin (2013) 0.82
The mitochondrial uncoupler DNP triggers brain cell mTOR signaling network reprogramming and CREB pathway up-regulation. J Neurochem (2015) 0.81
The associations between Parkinson's disease and cancer: the plot thickens. Transl Neurodegener (2015) 0.81
Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of aberrant cell cycle diseases: an update. ScientificWorldJournal (2012) 0.81
Akt as a victim, villain and potential hero in Parkinson's disease pathophysiology and treatment. Cell Mol Neurobiol (2011) 0.80
Trib3 Is Elevated in Parkinson's Disease and Mediates Death in Parkinson's Disease Models. J Neurosci (2015) 0.80
Glycolytic-to-oxidative fiber-type switch and mTOR signaling activation are early-onset features of SBMA muscle modified by high-fat diet. Acta Neuropathol (2016) 0.80
Rapamycin and interleukin-1β impair brain-derived neurotrophic factor-dependent neuron survival by modulating autophagy. J Biol Chem (2014) 0.80
Age and α-synuclein expression interact to reveal a dependence of dopaminergic axons on endogenous Akt/PKB signaling. Neurobiol Dis (2011) 0.80
Dopamine prevents lipid peroxidation-induced accumulation of toxic α-synuclein oligomers by preserving autophagy-lysosomal function. Front Cell Neurosci (2013) 0.80
Reversal of phenotypes of cellular senescence by pan-mTOR inhibition. Aging (Albany NY) (2016) 0.80
G1/S Cell Cycle Checkpoint Dysfunction in Lymphoblasts from Sporadic Parkinson's Disease Patients. Mol Neurobiol (2014) 0.79
Rapamycin improves peripheral nerve myelination while it fails to benefit neuromuscular performance in neuropathic mice. Neurobiol Dis (2014) 0.79
Rapamycin is neuroprotective in a rat chronic hypertensive glaucoma model. PLoS One (2014) 0.79
Activation of mTOR ameliorates fragile X premutation rCGG repeat-mediated neurodegeneration. PLoS One (2013) 0.79
Targeting the Autophagy/Lysosomal Degradation Pathway in Parkinson´s Disease. Curr Neuropharmacol (2016) 0.78
Parkinson's disease: don't mess with calcium. J Clin Invest (2012) 0.78
Rapamycin promotes Schwann cell migration and nerve growth factor secretion. Neural Regen Res (2014) 0.78
Comparative mRNA Expression of eEF1A Isoforms and a PI3K/Akt/mTOR Pathway in a Cellular Model of Parkinson's Disease. Parkinsons Dis (2016) 0.78
RTP801/REDD1: a stress coping regulator that turns into a troublemaker in neurodegenerative disorders. Front Cell Neurosci (2014) 0.77
The critical roles of mitophagy in cerebral ischemia. Protein Cell (2016) 0.77
Cell Death-Autophagy Loop and Glutamate-Glutamine Cycle in Amyotrophic Lateral Sclerosis. Front Mol Neurosci (2017) 0.77
A genetic screen identifies Tor as an interactor of VAPB in a Drosophila model of amyotrophic lateral sclerosis. Biol Open (2014) 0.77
Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indications. Pharmaceuticals (Basel) (2012) 0.77
A new method to measure autophagy flux in the nervous system. Autophagy (2014) 0.77
Rapamycin prevents cadmium-induced neuronal cell death via targeting both mTORC1 and mTORC2 pathways. Neuropharmacology (2015) 0.77
Mitochondrial dynamics and mitophagy in the 6-hydroxydopamine preclinical model of Parkinson's disease. Parkinsons Dis (2012) 0.77
A knockout of the caspase 2 gene produces increased resistance of the nigrostriatal dopaminergic pathway to MPTP-induced toxicity. Exp Neurol (2011) 0.77
PINK1 deficiency enhances autophagy and mitophagy induction. Mol Cell Oncol (2015) 0.76
A Drosophila Model of Neuronopathic Gaucher Disease Demonstrates Lysosomal-Autophagic Defects and Altered mTOR Signalling and Is Functionally Rescued by Rapamycin. J Neurosci (2016) 0.76
Rapamycin inhibits Erk1/2-mediated neuronal apoptosis caused by cadmium. Oncotarget (2015) 0.76
Autophagy regulates colistin-induced apoptosis in PC-12 cells. Antimicrob Agents Chemother (2015) 0.76
Toll-like receptor 2 is increased in neurons in Parkinson's disease brain and may contribute to alpha-synuclein pathology. Acta Neuropathol (2016) 0.76
The Degradation Pathway of the Mitophagy Receptor Atg32 Is Re-Routed by a Posttranslational Modification. PLoS One (2016) 0.75
Loss of NEDD4 contributes to RTP801 elevation and neuron toxicity: implications for Parkinson's disease. Oncotarget (2016) 0.75
Autophagy Promoted the Degradation of Mutant ATXN3 in Neurally Differentiated Spinocerebellar Ataxia-3 Human Induced Pluripotent Stem Cells. Biomed Res Int (2016) 0.75
Therapeutic Manipulation of Ageing: Repurposing Old Dogs and Discovering New Tricks. EBioMedicine (2016) 0.75
Therapeutic potential of autophagy-enhancing agents in Parkinson's disease. Mol Neurodegener (2017) 0.75
A central role for TOR signalling in a yeast model for juvenile CLN3 disease. Microb Cell (2015) 0.75
Rapamycin upregulates glutamate transporter and IL-6 expression in astrocytes in a mouse model of Parkinson's disease. Cell Death Dis (2017) 0.75
Rapamycin Reduced Ischemic Brain Damage in Diabetic Animals Is Associated with Suppressions of mTOR and ERK1/2 Signaling. Int J Biol Sci (2016) 0.75
Influence of miR-155 on Cell Apoptosis in Rats with Ischemic Stroke: Role of the Ras Homolog Enriched in Brain (Rheb)/mTOR Pathway. Med Sci Monit (2016) 0.75
Mammalian target of rapamycin (mTOR) as a potential therapeutic target in various diseases. Inflammopharmacology (2017) 0.75
Biomarker Research in Parkinson's Disease Using Metabolite Profiling. Metabolites (2017) 0.75
Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci U S A (1976) 21.06
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 18.36
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol (2004) 16.83
Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol (1997) 15.32
Parkinson's disease: mechanisms and models. Neuron (2003) 14.84
Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet (2004) 14.31
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem (2009) 12.73
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol (2004) 12.12
Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science (1997) 11.48
SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell (2006) 10.50
Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science (1997) 8.81
Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell (1992) 8.51
RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci U S A (1998) 8.03
Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene (2004) 7.92
PI3K: downstream AKTion blocks apoptosis. Cell (1997) 7.73
Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol (2004) 7.59
Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev (2004) 7.51
Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A (2008) 6.84
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene (2006) 6.54
Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem (1995) 5.57
Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science (1992) 5.00
Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev (2008) 4.52
A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans (2009) 4.37
A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol (2000) 4.25
Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol (1997) 3.80
Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem (2005) 3.56
Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol Cell Biol (2002) 3.30
Regulation of autophagy by extracellular signal-regulated protein kinases during 1-methyl-4-phenylpyridinium-induced cell death. Am J Pathol (2007) 3.29
REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell (2002) 3.29
Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol Cell Biol (2005) 3.14
Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins. Proc Natl Acad Sci U S A (1994) 3.09
Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. J Neurosci (2009) 2.90
Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease. J Neurosci (2002) 2.83
Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration (1995) 2.71
Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. Cell Death Differ (2008) 2.65
Rapamycin pre-treatment protects against apoptosis. Hum Mol Genet (2006) 2.57
Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle (2009) 2.45
TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin. J Biol Chem (1995) 2.39
Role of mTOR in physiology and pathology of the nervous system. Biochim Biophys Acta (2007) 2.19
Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain (2007) 2.10
In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience (1997) 2.07
Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLoS One (2009) 1.88
Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes. Endocrinology (2004) 1.71
Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res (2003) 1.69
Invited article: changing concepts in Parkinson disease: moving beyond the decade of the brain. Neurology (2008) 1.66
Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2001) 1.62
Rapid turnover of the mTOR complex 1 (mTORC1) repressor REDD1 and activation of mTORC1 signaling following inhibition of protein synthesis. J Biol Chem (2007) 1.52
Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease. Proc Natl Acad Sci U S A (2006) 1.51
REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase. Oncogene (2005) 1.49
Dexamethasone-induced gene 2 (dig2) is a novel pro-survival stress gene induced rapidly by diverse apoptotic signals. J Biol Chem (2003) 1.47
Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. Apoptosis (2009) 1.43
Small molecule enhancers of autophagy for neurodegenerative diseases. Mol Biosyst (2008) 1.39
RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation. J Neurosci (2008) 1.37
Death in the balance: alternative participation of the caspase-2 and -9 pathways in neuronal death induced by nerve growth factor deprivation. J Neurosci (2001) 1.36
Roles of autophagy and mTOR signaling in neuronal differentiation of mouse neuroblastoma cells. Cell Signal (2008) 1.31
Effects of rapamycin on gene expression, morphology, and electrophysiological properties of rat hippocampal neurons. Epilepsy Res (2007) 1.29
Role of mTOR in the degradation of IRS-1: regulation of PP2A activity. J Cell Biochem (2002) 1.25
RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation. J Neurosci (2006) 1.22
FKHRL1 and its homologs are new targets of nerve growth factor Trk receptor signaling. J Neurochem (2002) 1.18
Neural actions of immunophilin ligands. Trends Pharmacol Sci (1998) 1.18
Analysis of gene expression changes in a cellular model of Parkinson disease. Neurobiol Dis (2005) 1.08
Amelioration of protein misfolding disease by rapamycin: translation or autophagy? Autophagy (2008) 0.98
Therapeutic implications for immunophilin ligands in the treatment of neurodegenerative diseases. Curr Drug Targets CNS Neurol Disord (2003) 0.91
Medical treatment of Parkinson's disease. J Neurol (1998) 0.90
Immunophilin ligands and GDNF enhance neurite branching or elongation from developing dopamine neurons in culture. Exp Neurol (2000) 0.88
Immunophilins and their ligands: insights into survival and growth of human neurons. Physiol Behav (2002) 0.83
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Parkinson's disease: mechanisms and models. Neuron (2003) 14.84
PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci U S A (2009) 8.25
Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci (2007) 7.77
Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci (2002) 4.38
Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature (2002) 4.21
The kinase domain of mitochondrial PINK1 faces the cytoplasm. Proc Natl Acad Sci U S A (2008) 3.65
Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci (2009) 3.24
Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest (2008) 3.23
Mitochondria: the next (neurode)generation. Neuron (2011) 3.06
Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc (2007) 3.00
NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci U S A (2003) 2.91
DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci U S A (2007) 2.87
Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease. J Neurosci (2002) 2.83
Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci U S A (2003) 2.74
Toxin-induced models of Parkinson's disease. NeuroRx (2005) 2.67
Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A (2002) 2.64
Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci (2003) 2.31
D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Invest (2003) 2.25
Highly efficient small interfering RNA delivery to primary mammalian neurons induces MicroRNA-like effects before mRNA degradation. J Neurosci (2004) 2.22
Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer (2004) 2.20
Spinal cord endoplasmic reticulum stress associated with a microsomal accumulation of mutant superoxide dismutase-1 in an ALS model. Proc Natl Acad Sci U S A (2006) 2.10
CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism. J Neurochem (2005) 2.08
JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 2.05
Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 2.01
Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One (2008) 1.99
Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med (2012) 1.99
Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann N Y Acad Sci (2008) 1.92
The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis mice. Proc Natl Acad Sci U S A (2006) 1.90
Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2003) 1.87
Prion protein codon 129 genotype prevalence is altered in primary progressive aphasia. Ann Neurol (2005) 1.83
Genetic clues to the pathogenesis of Parkinson's disease. Nat Med (2004) 1.76
Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. J Neurosci (2003) 1.74
Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci U S A (2005) 1.68
Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. PLoS One (2008) 1.65
The MPTP model of Parkinson's disease. Brain Res Mol Brain Res (2005) 1.60
POSH acts as a scaffold for a multiprotein complex that mediates JNK activation in apoptosis. EMBO J (2003) 1.59
Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol (2002) 1.52
Pro-apoptotic Bim induction in response to nerve growth factor deprivation requires simultaneous activation of three different death signaling pathways. J Biol Chem (2007) 1.51
Nerve growth factor (NGF) down-regulates the Bcl-2 homology 3 (BH3) domain-only protein Bim and suppresses its proapoptotic activity by phosphorylation. J Biol Chem (2002) 1.51
Classic and new animal models of Parkinson's disease. J Biomed Biotechnol (2012) 1.45
Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. Apoptosis (2009) 1.43
The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proc Natl Acad Sci U S A (2009) 1.43
Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease. Proc Natl Acad Sci U S A (2007) 1.41
Mitophagy: the latest problem for Parkinson's disease. Trends Mol Med (2010) 1.41
Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. J Neurosci (2005) 1.40
RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation. J Neurosci (2008) 1.37
Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease. Neurotox Res (2009) 1.35
Regulated expression of ATF5 is required for the progression of neural progenitor cells to neurons. J Neurosci (2003) 1.31
Alpha-synuclein overexpression increases cytosolic catecholamine concentration. J Neurosci (2006) 1.30
Bim is a direct target of a neuronal E2F-dependent apoptotic pathway. J Neurosci (2005) 1.29
Inflammation in ALS and SMA: sorting out the good from the evil. Neurobiol Dis (2009) 1.29
The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines. Int J Cancer (2007) 1.27
Nitric oxide and reactive oxygen species in Parkinson's disease. IUBMB Life (2003) 1.26
Pathogenic role of glial cells in Parkinson's disease. Mov Disord (2003) 1.25
Regulation of neuron survival and death by p130 and associated chromatin modifiers. Genes Dev (2005) 1.25
RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation. J Neurosci (2006) 1.22
The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci (2000) 1.22
Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis. Amyotroph Lateral Scler Frontotemporal Degener (2013) 1.21
Mitochondrial dynamics and bioenergetic dysfunction is associated with synaptic alterations in mutant SOD1 motor neurons. J Neurosci (2012) 1.19
Fractalkine: moving from chemotaxis to neuroprotection. Nat Neurosci (2006) 1.19
Neurodegeneration and inflammation in Parkinson's disease. Parkinsonism Relat Disord (2012) 1.19
A tale on animal models of Parkinson's disease. Mov Disord (2011) 1.18
Mitochondrial autophagy in cells with mtDNA mutations results from synergistic loss of transmembrane potential and mTORC1 inhibition. Hum Mol Genet (2011) 1.18
Programmed cell death in amyotrophic lateral sclerosis. J Clin Invest (2003) 1.17
Siah1 interacts with the scaffold protein POSH to promote JNK activation and apoptosis. J Biol Chem (2005) 1.17
Instrumental activation of bid by caspase-1 in a transgenic mouse model of ALS. Mol Cell Neurosci (2002) 1.17
Enriched environment confers resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and cocaine: involvement of dopamine transporter and trophic factors. J Neurosci (2003) 1.16
Downregulation of activating transcription factor 5 is required for differentiation of neural progenitor cells into astrocytes. J Neurosci (2005) 1.15
Bim is elevated in Alzheimer's disease neurons and is required for beta-amyloid-induced neuronal apoptosis. J Neurosci (2007) 1.14
α-Synuclein is localized to mitochondria-associated ER membranes. J Neurosci (2014) 1.13
Pathogenesis of Parkinson's disease. Mov Disord (2012) 1.13
Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci (2004) 1.13
Identification of a novel DNA binding site and a transcriptional target for activating transcription factor 5 in c6 glioma and mcf-7 breast cancer cells. Mol Cancer Res (2009) 1.12
Neurodegeneration: what is it and where are we? J Clin Invest (2003) 1.11
Multimodal actions of neural stem cells in a mouse model of ALS: a meta-analysis. Sci Transl Med (2012) 1.10